Pfizer's GLP-1 drug showed 12% weight loss over six months with just one monthly injection. Experts say it could be years before it receives regulatory approval ...
Pfizer has reported promising mid-stage trial results for berobenatide, an experimental weight-loss and diabetes medication that could become the world's first once-a-month GLP-1 injection if approved ...
Pharmaceutical giant Pfizer has unveiled encouraging mid-stage trial results for berobenatide, an experimental anti-obesity and diabetes drug designed to be taken just once a month. If approved, it ...
Add Yahoo as a preferred source to see more of our stories on Google. Pfizer's GLP-1 drug showed 12% weight loss over six months with just one monthly injection. Experts say it could be years before ...